Navigation Links
Change in Course of Treatment: Exploring Better Ways

At the Annual Meeting of the American Society of Clinical Oncology today, the results of a large, multicenter, international study laying the groundwork for decisions that included when or if a change in treatment should be made were presented.

In patients with metastatic colorectal cancer, counting circulating tumor cells before and after the start of treatment could help doctors decide when and if a change in course of treatment is necessary.

Few studies have examined the relationship of CTC and a patient's prognosis in cancer. This is an important area of research in metastatic colorectal cancer because there are little data to help physicians chose which treatment is best for which patients or to determine when a change in treatment is warranted.

"If we had a way to know early on that a tumor isn't responding to a particular drug, we could switch to a different treatment before growth of the cancer is seen on a CAT scan," said Neal J. Meropol, director of the gastrointestinal cancer program at Fox Chase Cancer Center and lead investigator of the study. "If we could determine that the tumor was destined to grow after a few weeks of treatment, we'd be able alter course even before the first scan."

For this study, Meropol and his colleagues examined the association between the circulating tumor cell number and progression-free and overall survival for 430 adult patients with metastatic colorectal cancer.

The number of CTC was measured at baseline, one month, and several other points after the start of treatment. CTC were isolated and counted by an immunomagnetic cell separation technique, an FDA-approved technology developed by Immunicon Corporation. CT scans were obtained in usual practiceat baseline and every 6-12 weeks after starting treatment. Having 3 or more CTC (per 7.5 mL of blood) was defined as "unfavorable" in an initial analysis. Patients with fewer than 3 CTC were considered favorab le.

Before initiation of the first treatment (baseline), 53 percent of patients had no detectable CTC. These patients had superior median survival times compared with those patients who had circulating tumor cells. A favorable CTC number before treatment is associated with better progression free survival and overall survival.

In addition to its predictive value at baseline, the CTC was also a strong indicator of prognosis as early as 3-5 weeks after treatment initiation. "Patients with unfavorable CTC had a shorter median survival time. This was even seen in those patients whose CT scan the gold standard for tumor evaluation- indicated no disease progression," Meropol explained.

The median overall survival of patients with a favorable CTC before treatment was almost double that of those with an unfavorable CTC (18.5 months vs. 9.4 months). Patients with a favorable CTC had a median progression free survival of 7.9 months and those with an unfavorable CTC had a progression free survival of 4.5 months. The measurement of CTCs consistently provided prognostic information even when tested at 6-12 weeks.

Another key finding was the predictive value of a change in CTC. Among patients with unfavorable CTC at baseline, those whose numbers decreased after treatment to fewer than 3 had improved progression-free survival and overall survival.

"Potentially, this tool could be useful in the clinic to make real-time decisions about whether a treatment is helping. Our ultimate goal is to continue effective treatment, but spare patients the side effects of a treatment that is destined to fail. This is the direction that future studies must take."


'"/>




Related medicine news :

1. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
2. Change in walking might indicate Dementia
3. Change in weight not a risk in healthy men
4. Changes in cabin pressure pose risks for moms-to-be
5. Dietary Changes Could Reduce The Risk for Stroke
6. Link Between High Blood Sugar And Behavioral Changes
7. Improving Lighting Could Bring About A Change In Alzheimers Patients
8. Specific Changes In A Particular Gene Found To Increase The Risk of Alzheimer’s Diseas
9. Impotence Drugs Ordered by FDA to have Label Change
10. Ultrasounds To Detect Changes In Heart Motions
11. Change In Diet May Slow The Progression Of Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
Breaking Medicine Technology: